NGNE NASDAQ
Neurogene Inc.
1W: +6.3%
1M: -5.2%
3M: -19.8%
YTD: +33.9%
1Y: -9.7%
3Y: +105.7%
5Y: -80.8%
$26.99
+3.45 (+14.66%)
Weekly Expected Move ±10.7%
$18
$21
$24
$26
$29
Credit Risk of going bust: lower than 55% of companies Debt: 2.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.08 (down 99.7%), Neurogene Inc. would be worth roughly what it owes.
Total debt $8.3M against a stock market value of $372.0M.
Distance to default 5.60 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.2M (short-term plus half of long-term), stock volatility 76.8%; Altman Z'' 5.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.08 (down 99.7%), Neurogene Inc. would be worth roughly what it owes.
Total debt $8.3M against a stock market value of $372.0M.
Distance to default 5.60 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.2M (short-term plus half of long-term), stock volatility 76.8%; Altman Z'' 5.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (27)
Neurogene Inc. (NASDAQ:NGNE) Stock Has Average Target Price of $80.29 According to Brokerages
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Neurogene (NASDAQ:NGNE) Sees Large Volume Increase – Should You Buy?
Neurogene is a new Overweight at J.P. Morgan on Rett syndrome therapy
Neurogene Inc. (NASDAQ:NGNE) Stock Has Consensus Price Target of $83.67
Bank of America Corp DE Trims Stock Holdings in Neurogene Inc. $NGNE
Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNE
BlackRock Inc. Invests $33.27 Million in Neurogene Inc. $NGNE
Neurogene Inc. (NASDAQ:NGNE) Receives $84.83 Consensus PT from Analysts
Neurogene (NASDAQ:NGNE) Shares Up 0.1% – Here’s What Happened
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $44.00
Equities Analysts Set Expectations for Neurogene Q1 Earnings
HC Wainwright Weighs in on Neurogene FY2027 Earnings
Q1 Earnings Estimate for Neurogene Issued By Lifesci Capital
Neurogene GAAP EPS of -$4.24 beats by $0.04
Neurogene Inc. (NASDAQ:NGNE) Receives $44.00 Consensus Price Target from Analysts
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy
Neurogene Inc. (NASDAQ:NGNE) Receives $44.00 Average Price Target from Analysts
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit
Neurogene to Participate in Upcoming Investor Conferences
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene: From Speculation To Execution With NGN-401